

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT4134497

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
GILES DESMADRYL	08/22/2011
CHRISTIAN CHABBERT	08/22/2011
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE
<b>Street Address:</b>	101 RUE DE TOLBIAC
<b>City:</b>	PARIS
<b>State/Country:</b>	FRANCE
<b>Postal Code:</b>	F-75013
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	13141652
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(512)536-4598
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	512 536 3045
<b>Email:</b>	aoipdocket@nortonrosefulbright.com
<b>Correspondent Name:</b>	NORTON ROSE FULBRIGHT US LLP
<b>Address Line 1:</b>	98 SAN JACINTO BLVD
<b>Address Line 2:</b>	STE 1100
<b>Address Line 4:</b>	AUSTIN, TEXAS 78701
<b>ATTORNEY DOCKET NUMBER:</b>	ICOS.P0008US.C1
<b>NAME OF SUBMITTER:</b>	MARK B. WILSON
<b>SIGNATURE:</b>	/Mark B. Wilson/
<b>DATE SIGNED:</b>	11/09/2016
<b>Total Attachments: 2</b>	
source=ICOS.P008US.C1 Assignment#page1.tif	
source=ICOS.P008US.C1 Assignment#page2.tif	

ASSIGNMENT

FOR GOOD AND VALUABLE CONSIDERATION, the receipt, sufficiency and adequacy of which are hereby acknowledged, the undersigned, do hereby:

SELL, ASSIGN AND TRANSFER to INSERM (Institut national de la santé et de la recherche médicale) (the "Assignee"), having a place of business at 101, rue de Tolbiac, F-75013 Paris, France, the entire right, title and interest for the United States and all foreign countries in and to any and all improvements which are disclosed in the application for United States Letters Patent, Serial No. 13/141,652 which has been filed on **June 22, 2011** and is entitled **"SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS,"** which is a national phase application under 35 U.S.C. § 371 of international application No. PCT/EP2009/067897, such application and all divisional, continuing, substitute, renewal, reissue and all other applications for patent which have been or shall be filed in the United States and all foreign countries on any of such improvements; all original and reissued patents which have been or shall be issued in the United States and all foreign countries on such improvements; and specifically including the right to file foreign applications under the provisions of any convention or treaty and claim priority based on such application in the United States;

AUTHORIZE AND REQUEST the issuing authority to issue any and all United States and foreign patents granted on such improvements to the Assignee;

WARRANT AND COVENANT that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been or will be made to others by the undersigned, and that the full right to convey the same as herein expressed is possessed by the undersigned;

COVENANT, when requested and at the expense of the Assignee, to carry out in good faith the intent and purpose of this assignment, the undersigned will execute all divisional, continuing, substitute, renewal, reissue, and all other patent applications on any and all such improvements; execute all rightful oaths, declarations, assignments, powers of attorney and other papers; communicate to the Assignee all facts known to the undersigned relating to such improvements and the history thereof; and generally do everything possible which the Assignee shall consider desirable for vesting title to such improvements in the Assignee, and for securing, maintaining and enforcing proper patent protection for such improvements;

TO BE BINDING on the heirs, assigns, representatives and successors of the undersigned and extend to the successors, assigns and nominees of the Assignee.

The assignment of said invention is effective as of the earlier of (1) the date of execution shown below or (2) the filing date of the first filed of said patent applications.

Signature: \_\_\_\_\_  
Name: Giles DESMADRYL

Date: 08/22/2011

BEFORE ME, the undersigned authority, on this 22 day of August, 2011 personally appeared Giles DESMADRYL, known to me to be the person whose name is subscribed to the foregoing instrument and acknowledged to me that he/she executed the same of his/her own free will for the purposes and consideration therein expressed.

**Witness**

Signature: \_\_\_\_\_  
Name: Christian CHABBERT

Date: 08/22/2024

BEFORE ME, the undersigned authority, on this 22 day of August, 2011 personally appeared Christian CHABBERT, known to me to be the person whose name is subscribed to the foregoing instrument and acknowledged to me that he/she executed the same of his/her own free will for the purposes and consideration therein expressed.

**Witness**

**FULBRIGHT & JAWORSKI L.L.P.**  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701